Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Oncology

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.35.4837PMID 22529257
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.

  2011cited by this paper
• A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancer.

  2010cited by this paper
• Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

  2010cited by this paper
• A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II).

  2009cited by this paper
• US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.

  2009cited by this paper
• Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: A treatment planning comparison with fixed field IMRT.

  2009cited by this paper
• Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).

  2009cited by this paper
• EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.

  2008cited by this paper
• Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

  2008cited by this paper
• Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

  2008cited by this paper
• Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).

  2008cited by this paper
• Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?

  2007influential reference
• Epidermoid Carcinoma of the Anal Canal

  2002cited by this paper
• High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.

  2001cited by this paper
• Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.

  1998cited by this paper
• Induction chemotherapy and radiotherapy in loco-regionally advanced epidermoid carcinoma of the anal canal.

  1998cited by this paper
• Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

  1997influential reference
• 136 Dose escalation without split-course chemoradiation for anal cancer: Results of a phase II RTOG study

  1997influential reference
• Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

  1996influential reference
• Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

  1996cited by this paper
• Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study.

  1996cited by this paper
• Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

  1996cited by this paper
• Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.

  1996influential reference
• Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.

  1996cited by this paper
• EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale.

  1995cited by this paper
• Late effects toxicity scoring: the SOMA scale

  1995cited by this paper
• EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale.

  1995cited by this paper
• Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin.

  1993cited by this paper
• Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C.

  1991cited by this paper
• Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.

  1991cited by this paper
• Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal.

  1989cited by this paper
• Epidermoid carcinoma of the anal canal

  1987cited by this paper
• Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma.

  1985cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper

• Risk Factors for Colostomy after Chemoradiotherapy in Patients with Squamous Cell Carcinoma of the Anus: A Nationwide, Multicenter Analysis in Japan

  2026cites this paper
• Induction chemotherapy followed by chemoradiotherapy in patients with locally advanced anal cancers: The PRODIGE 85-FFCD 1804-KANALRAD trial.

  2026cites this paper
• Long-term outcomes and anorectal functional status of patients with anal squamous cell carcinoma treated with the modern technique of intensity-modulated radiotherapy

  2026cites this paper
• A systematic review and meta-analysis of blood-based biomarkers in anal squamous cell cancer treated with chemoradiotherapy.

  2026cites this paper
• SEOM-GEMCAD-TTD clinical guidelines for anal cancer (2025).

  2026cites this paper
• Inguinal CTV contouring in anal cancer: comparative validation of inguinal lymph nodes contouring guidelines and implications for consensus.

  2026cites this paper
• Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma - Authors' reply.

  2026cites this paper
• Outcomes of Anal Cancer Patients with Inflammatory Bowel Disease Treated with Curative Chemoradiotherapy: A Systematic Review of Current Evidence

  2025cites this paper
• Treatment of anal cancer in older patients and patients with frailty

  2025cites this paper
• Modest radiation dose escalation for early-stage anal cancer: cancer control and toxicity outcomes

  2025cites this paper
• Advances in Radiation Therapy for Anal Cancer

  2025cites this paper
• Comparative evaluation of TNM staging systems (eighth vs. ninth edition) for the non-surgical treatment of localized and locally advanced anal squamous cell carcinoma: Prognostic significance of T classification and lymph node status

  2025cites this paper
• Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.

  2025cites this paper
• The historical perspective on anal cancer therapy: what have we learnt, where did we fail?

  2025cites this paper
• Neoadjuvant and adjuvant chemotherapy in anal cancer – is there a role in the future?

  2025cites this paper
• Management of Localized and Locally Advanced Anal Cancer.

  2025cites this paper
• Prognosis Prediction and Surgical Benefit Subgroup Analysis in Anal Squamous Cell Carcinoma Patients Undergoing Concurrent Chemoradiotherapy

  2025cites this paper
• Development of a Predictive Calculator for the Need for Abdominoperineal Resection after Chemoradiation Therapy in Anal Squamous Cell Carcinoma.

  2025cites this paper
• Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

  2025cites this paper
• Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique.

  2025cites this paper
• Very Late-Onset Serious Chronic Adverse Effects After Radical Chemoradiotherapy for Anal Canal Cancer

  2025influential citation
• Advances in the Management, Treatment, and Surveillance of Anal Squamous Cell Cancer

  2025cites this paper
• The prognostic value of cell‐free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus

  2025cites this paper
• Radio(chemo)therapy with curative intent for anal cancer – effectiveness and toxicity in elderly vs. younger patients

  2025cites this paper
• Optimising chemoradiotherapy in anal cancer

  2025cites this paper
• Cancer anal : traitements

  2025cites this paper
• Innovative radiotherapy approaches

  2025cites this paper
• Impact of perineal healing on oncological outcome following surgery for squamous cell carcinoma of the anus

  2025cites this paper
• Management of oligometastatic anal cancer—a literature review and a proposed treatment algorithm

  2025cites this paper
• Cancer anal : épidémiologie, histologie, clinique, exploration

  2025cites this paper
• Advances in anal cancer treatment: current standards, the role of immunotherapy and emerging strategies

  2025cites this paper
• Personalising anal cancer radiotherapy dose (PLATO): protocol for a multicentre integrated platform trial

  2025cites this paper
• Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial.

  2025cites this paper
• Management of Squamous Cell Carcinomas of the Anal Canal and Anal Margin After Failure of Chemoradiotherapy Treatment: A Narrative Review

  2025cites this paper
• Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline

  2024cites this paper
• International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set

  2024cites this paper
• Anal Squamous Cell Carcinoma: From Standard Treatment to Personalized Therapy

  2024cites this paper
• Navigating the Complexities of Radiation Injuries: Therapeutic Principles and Reconstructive Strategies

  2024cites this paper
• PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement

  2024cites this paper
• Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan

  2024cites this paper
• HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy

  2024cites this paper
• Progress in the treatment of anal cancer: an overview of the latest investigational drugs

  2024cites this paper
• Squamous cell carcinoma of the anus successfully treated with multidisciplinary therapy for metachronous metastatic and local recurrences after DCF chemotherapy: a case report

  2024cites this paper
• Treatment of stage I-III squamous cell anal cancer: a comparative effectiveness systematic review

  2024cites this paper
• Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation

  2024cites this paper
• Feasibility of weekly cisplatin and radiotherapy for localized anal cancer - A Danish anal cancer group report.

  2024cites this paper
• Interstitial HDR brachytherapy for anal cancer—results and quality of life

  2024cites this paper
• Prognostic Significance of Bulky Nodal Disease in Anal Cancer Management: A Multi-institutional Study

  2024cites this paper
• Adenocarcinoma of the Anal Glands: A Case Report and Literature Review

  2024cites this paper
• Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: results of the FFCD 0904 phase II trial.

  2023cites this paper
• Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study

  2023cites this paper
• The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments.

  2023cites this paper
• Anal Cancer: The Past, Present and Future

  2023influential citation
• Radiothérapie du cancer du rectum et du canal anal

  2023cites this paper
• Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

  2023cites this paper
• Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.

  2023cites this paper
• Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE.

  2023cites this paper
• Tumor, patient, and social determinants of health affecting survival in patients with anal cancer treated by chemoradiation.

  2023cites this paper
• Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma

  2023influential citation
• Was muss der Allgemein- und Viszeralchirurg von der onkologisch ausgerichteten Strahlentherapie wissen?

  2023cites this paper
• Magnetic resonance imaging of anal cancer: tumor characteristics and early prediction of treatment outcome

  2023cites this paper
• Radiotherapy in the management of rare gastrointestinal cancers: A systematic review.

  2023cites this paper
• Recent Advances in the Management of Anal Cancer

  2023influential citation
• Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort

  2023cites this paper
• Prognostic factors for patients with anal cancer treated with conformal radiotherapy—a systematic review

  2022cites this paper
• "Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC).

  2022cites this paper
• Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis

  2022influential citation
• Anal cancer brachytherapy: from radon seeds to Papillon technique in a century. What does the future hold?

  2022cites this paper
• Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution

  2022cites this paper
• Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results

  2022cites this paper
• Impact of Definitive Chemoradiation on Quality-of-Life Changes for Patients With Anal Cancer: Long-term Results of a Prospective Study

  2022cites this paper
• Compliance to chemoradiation in squamous cell carcinoma of the anus.

  2022cites this paper
• Factors Affecting Clinical Outcomes Among Patients Infected With HIV and Anal Cancer Treated With Modern Definitive Chemotherapy and Radiation Therapy

  2022cites this paper
• Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation

  2022cites this paper
• Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial

  2022cites this paper
• A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10–2 trial)

  2022cites this paper
• Influence of radiation treatment technique (IMRT vs. 3D-RT) on acute toxicity and prognostic factors for survival for anal cancer

  2022cites this paper
• [Anal cancer: Focus on current treatment and future perspective].

  2022cites this paper
• Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

  2022cites this paper
• Online adaptive radiotherapy of anal cancer: normal tissue sparing, target propagation methods, and first clinical experience.

  2022cites this paper
• Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma

  2022cites this paper
• Management and Outcomes in Anal Canal Adenocarcinomas—A Systematic Review

  2022cites this paper
• Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study

  2022cites this paper
• Failure of Initial Curative Treatment for Non-Metastatic Anal Squamous Cell Carcinoma: From Prognostic Factors Analysis to Stratified Treatment.

  2022cites this paper
• The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies

  2022cites this paper
• Hypoxia and local tumour control in squamous cell carcinoma of the anus – a hypothesis-generating study

  2022cites this paper
• Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies

  2022cites this paper
• A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer

  2022cites this paper
• Pretreatment colostomy in patients with anal squamous cell carcinoma: Risk factors for a permanent stoma

  2022cites this paper
• Chemoradiation vs. local excision in the management of early squamous cell carcinoma of the anus: a systematic review

  2022cites this paper
• Anal Cancer-Diagnosis, Treatment and Follow-up.

  2021cites this paper
• Cisplatin/capecitabine with intensity-modulated radiation therapy in anal squamous cell carcinoma: a preliminary study

  2021cites this paper
• State of the art treatment for stage I to III anal squamous cell carcinoma: a systematic review and meta-analysis.

  2021influential citation
• Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience

  2021cites this paper
• MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma

  2021cites this paper
• Current treatment and future directions in the management of anal cancer

  2021cites this paper
• A Pattern of Care Report on the Management of Patients with Squamous Cell Carcinoma of the Anus—A Study by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group

  2021cites this paper
• Radiotherapy of anal canal cancer.

  2021cites this paper
• [Squamous cell anal carcinoma. What's next ?]

  2021cites this paper